Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas

• Verfasst von: Röhrich, Manuel [VerfasserIn]
• Verfasst von: Huang, Kristin [VerfasserIn]
• Verfasst von: Schrimpf, Daniel [VerfasserIn]
• Verfasst von: Deimling, Andreas von [VerfasserIn]
• Verfasst von: Dimitrakopoulou-Strauss, Antonia [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Titel: Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas
• Verf.angabe: Manuel Röhrich, Kristin Huang, Daniel Schrimpf, Nathalie L. Albert, Thomas Hielscher, Andreas von Deimling, Ulrich Schüller, Antonia Dimitrakopoulou-Strauss, Uwe Haberkorn
• E-Jahr: 2018
• Jahr: 7 May 2018
• Umfang: 12 S.
• Teil: volume:45
• Teil: year:2018
• Teil: number:9
• Teil: pages:1573-1584
• Teil: extent:12
• Fussnoten: Gesehen am 14.04.2020
• Titel Quelle: Enthalten in: European journal of nuclear medicine and molecular imaging
• Ort Quelle: Heidelberg [u.a.] : Springer-Verl., 2002
• Jahr Quelle: 2018
• Band/Heft Quelle: 45(2018), 9, Seite 1573-1584
• ISSN Quelle: 1619-7089
• DOI: doi:10.1007/s00259-018-4009-0
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 169449070X

Abstract

Dynamic 18F-FET PET/CT is a powerful tool for the diagnosis of gliomas.18F-FET PET time-activity curves (TAC) allow differentiation between histological low-grade gliomas (LGG) and high-grade gliomas (HGG). Molecular methods such as epigenetic profiling are of rising importance for glioma grading and subclassification. Here, we analysed dynamic 18F-FET PET data, and the histological and epigenetic features of 44 gliomas. Dynamic 18F-FET PET was performed in 44 patients with newly diagnosed, untreated glioma: 10 WHO grade II glioma, 13 WHO grade III glioma and 21 glioblastoma (GBM). All patients underwent stereotactic biopsy or tumour resection after 18F-FET PET imaging. As well as histological analysis of tissue samples, DNA was subjected to epigenetic analysis using the Illumina 850 K methylation array. TACs, standardized uptake values corrected for background uptake in healthy tissue (SUVmax/BG), time to peak (TTP) and kinetic modelling parameters were correlated with histological diagnoses and with epigenetic signatures. Multivariate analyses were performed to evaluate the diagnostic accuracy of 18F-FET PET in relation to the tumour groups identified by histological and methylation-based analysis. Epigenetic profiling led to substantial tumour reclassification, with six grade II/III gliomas reclassified as GBM. Overlap of HGG-typical TACs and LGG-typical TACs was dramatically reduced when tumours were clustered on the basis of their methylation profile. SUVmax/BG values of GBM were higher than those of LGGs following both histological diagnosis and methylation-based diagnosis. The differences in TTP between GBMs and grade II/III gliomas were greater following methylation-based diagnosis than following histological diagnosis. Kinetic modeling showed that relative K1 and fractal dimension (FD) values significantly differed in histology- and methylation-based GBM and grade II/III glioma between those diagnosed histologically and those diagnosed by methylation analysis. Multivariate analysis revealed slightly greater diagnostic accuracy with methylation-based diagnosis. IDH-mutant gliomas and GBM subgroups tended to differ in their 18F-FET PET kinetics. The status of dynamic 18F-FET PET as a biologically and clinically relevant imaging modality is confirmed in the context of molecular glioma diagnosis.